Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma

Abstract

Edited by Paul E. Fraser FUS and EWSR1 are RNA-binding proteins with prion-like domains (PrLDs) that aggregate in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The FUS and EWSR1 genes are also prone to chromosomal translocation events, which result in aberrant fusions between portions of the PrLDs of FUS and EWSR1 and the transcription factors CHOP and FLI. The resulting fusion proteins, FUS-CHOP and EWS-FLI, drive aberrant transcriptional programs that underpin liposarcoma and Ewing's sarcoma, respectively. The translocated PrLDs alter the expression profiles of these proteins and promote their phase separation and aggregation. Here, we report the development of yeast models of FUS-CHOP and EWS-FLI toxicity and aggregation. These models recapitulated several salient features of sarcoma patient cells harboring the FUS-CHOP and EWS-FLI translocations. To reverse FUS and EWSR1 aggregation, we have explored Hsp104, a hexameric AAA؉ protein disaggregase from yeast. Previously, we engineered potentiated Hsp104 variants to suppress the proteotoxicity, aggregation, and mislocalization of FUS and other proteins that aggregate in ALS/FTD and Parkinson's disease. Potentiated Hsp104 variants that robustly suppressed FUS toxicity and aggregation also suppressed the toxicity and aggregation of FUS-CHOP and EWS-FLI. We suggest that these new yeast models are powerful platforms for screening for modulators of FUS-CHOP and EWS-FLI phase separation. Moreover, Hsp104 variants might be employed to combat the toxicity and phase separation of aberrant fusion proteins involved in sarcoma.Chromosomal translocation events underpin sarcoma (1). In liposarcoma, the N-terminal portion of FUS 3 becomes aber-

Biomolecular condensates in neurodegeneration and cancer

“…High‐content screening has identified small molecules that modulate SG assembly, prevent accumulation of aggregation‐prone proteins in SGs and block protein aggregation and rescue neurodegenerative phenotypes . Moreover, a HSP104‐based disaggregase has been shown to attenuate phase separation of EWS‐FLI and FUS‐CHOP and reduce their toxicity in yeast models . Better understanding of biomolecular condensate regulation, with considerations for their phase behaviors and biophysical properties along with the development of innovative tools to manipulate or control them, will offer crucial insights into their functional roles, disease phenotypes and new treatment options.…”

Disruption of oncogenic targeting by ISWI via phosphorylation of a prion-like domain

“…An intriguing and emerging property of proteins containing PrLDs, such as FET proteins, is the ability to form phase-separated biomolecular condensates (Banani et al, 2017;Maharana et al, 2018;Ryan et al, 2019;Shin et al, 2017). As such, FET proteins can phase separate under physiological conditions, and perhaps most interestingly, these intrinsically disordered regions (IDRs) can be post-translationally modified to promote or prevent phase separation and other intermolecular interactions.…”

Identification of aberrantly methylated-differentially expressed genes and potential agents for Ewing’s sarcoma

“…Despite progress in the treatment of ES, the survival rate of ES remains poor 13 . Most patients diagnosed with ES have a chromosomal translocation 14 . Some researchers have reported that chromosomal translocation can facilitate widespread epigenetic alterations 15 .…”